/MLND

MLND Stock - Millendo Therapeutics, Inc.

Q: What is the analyst price target for MLND?

Analyst price target information is not currently available for MLND.

Q: What is MLND's market cap?

Market capitalization information is not currently available for MLND.

Healthcare|Biotechnology|NASDAQ

$1.06-5.36%

$0.06 (-5.36%) • Jun 28

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $1.17

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for MLND

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2017

FY2018

FY2019

FY2020

FY2024

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta0.48

52W High$41.55

52W Low$1.06

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2020	FY2019	FY2018	FY2017
Revenue	N/A	N/A	N/A	N/A	$295,000
Gross Profit	N/A	N/A	N/A	N/A	$-495,000
Gross Margin	N/A	N/A	N/A	N/A	-167.8%
Operating Income	N/A	$-35,972,000	$-45,399,000	$-26,874,000	$-46,576,000
Net Income	$-41,843,000	$-36,406,000	$-44,568,000	$-27,192,000	$-50,975,000
Net Margin	N/A	N/A	N/A	N/A	-17279.7%
EPS	$-1.50	$-28.95	$-48.77	$-263.65	$-321.49

Company Overview

Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.

Visit Website

Frequently Asked Questions about MLND

What is MLND's current stock price?

Millendo Therapeutics, Inc. (MLND) is currently trading at $1.06 per share. The stock has moved -5.36% today.

What is the analyst price target for MLND?

No analyst price targets are currently available for this stock.

What sector is Millendo Therapeutics, Inc. in?

Millendo Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.

What is MLND's market cap?

Millendo Therapeutics, Inc. has a market capitalization of $0.01 billion, making it a small-cap company.

Does MLND pay dividends?

No, Millendo Therapeutics, Inc. does not currently pay a dividend to shareholders.